Organon & Co. OGN NYSE · Healthcare · United States
$13.90 -0.07% -$0.01
Summary
53 / 100 · Bulios Score
What speaks for it
- The share price is below the Bulios Fair Price.
- Out of every 100 USD of revenue, 11 USD is left as free cash.
What to watch
- Earnings per share fell by 41% a year over the last 3 years.
- Repaying its net debt would take 5.5 years of operating profit.
- It cut its dividend by 70% last year.
- Out of every 100 USD of revenue, only 3.5 USD is left as net profit.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBy our assumptions the business is worth more than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 17.2 USD for 1 USD of yearly profit. Over the last five years it was 6.3 USD on average.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue fell by 1.0% a year over 5 years. Over the last 3 years it grew by 0.2% a year. Earnings per share fell by 41% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 47 USD
- Research and development 5.9 USD
- Sales and administration 28 USD
- Taxes and other 16 USD
- Net profit 3.5 USD
Net profit, industry median (Drug Manufacturers - General) 14 USD
Out of every 100 USD of revenue, 3.5 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 12.7 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 0.58%
- Paid out of profit
- 9.9%
You receive $0.08 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
Neutral- Buy 2
- Hold 4
- Sell 3
Today's price within the analysts' price targets
The average target of $11 is 21% below today's price. 22% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
The company reports no revenue by product.
By region
- Non-US 43%
- Europe And Canada 15%
- UNITED STATES 15%
- Latin America, Middle East, Russia And Africa 9.9%
- Asia Pacific and Japan 9.2%
- Other 8.5%
Non-US brings in 43% of revenue. UNITED STATES grew fastest, by 4.2% a year.
Segments in detail